These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 10910344)

  • 1. A triclosan-resistant bacterial enzyme.
    Heath RJ; Rock CO
    Nature; 2000 Jul; 406(6792):145-6. PubMed ID: 10910344
    [No Abstract]   [Full Text] [Related]  

  • 2. Triclosan targets lipid synthesis.
    McMurry LM; Oethinger M; Levy SB
    Nature; 1998 Aug; 394(6693):531-2. PubMed ID: 9707111
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular basis of triclosan activity.
    Levy CW; Roujeinikova A; Sedelnikova S; Baker PJ; Stuitje AR; Slabas AR; Rice DW; Rafferty JB
    Nature; 1999 Apr; 398(6726):383-4. PubMed ID: 10201369
    [No Abstract]   [Full Text] [Related]  

  • 4. Structural basis and mechanism of enoyl reductase inhibition by triclosan.
    Stewart MJ; Parikh S; Xiao G; Tonge PJ; Kisker C
    J Mol Biol; 1999 Jul; 290(4):859-65. PubMed ID: 10398587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystallographic analysis of triclosan bound to enoyl reductase.
    Roujeinikova A; Levy CW; Rowsell S; Sedelnikova S; Baker PJ; Minshull CA; Mistry A; Colls JG; Camble R; Stuitje AR; Slabas AR; Rafferty JB; Pauptit RA; Viner R; Rice DW
    J Mol Biol; 1999 Nov; 294(2):527-35. PubMed ID: 10610777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan.
    Priyadarshi A; Kim EE; Hwang KY
    Proteins; 2010 Feb; 78(2):480-6. PubMed ID: 19768684
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular basis for triclosan activity involves a flipping loop in the active site.
    Qiu X; Janson CA; Court RI; Smyth MG; Payne DJ; Abdel-Meguid SS
    Protein Sci; 1999 Nov; 8(11):2529-32. PubMed ID: 10595560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signature gene expression profile of triclosan-resistant Escherichia coli.
    Yu BJ; Kim JA; Pan JG
    J Antimicrob Chemother; 2010 Jun; 65(6):1171-7. PubMed ID: 20410062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.
    Hoang TT; Schweizer HP
    J Bacteriol; 1999 Sep; 181(17):5489-97. PubMed ID: 10464225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triclosan: a widely used biocide and its link to antibiotics.
    Schweizer HP
    FEMS Microbiol Lett; 2001 Aug; 202(1):1-7. PubMed ID: 11506900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New agents to combat malaria.
    Beeson JG; Winstanley PA; McFadden GI; Brown GV
    Nat Med; 2001 Feb; 7(2):149-50. PubMed ID: 11175835
    [No Abstract]   [Full Text] [Related]  

  • 12. X-ray crystallographic analysis of the complexes of enoyl acyl carrier protein reductase of Plasmodium falciparum with triclosan variants to elucidate the importance of different functional groups in enzyme inhibition.
    Maity K; Bhargav SP; Sankaran B; Surolia N; Surolia A; Suguna K
    IUBMB Life; 2010 Jun; 62(6):467-76. PubMed ID: 20503440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene.
    Marcinkeviciene J; Jiang W; Kopcho LM; Locke G; Luo Y; Copeland RA
    Arch Biochem Biophys; 2001 Jun; 390(1):101-8. PubMed ID: 11368521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA).
    Brenwald NP; Fraise AP
    J Hosp Infect; 2003 Oct; 55(2):141-4. PubMed ID: 14529640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK).
    Marrakchi H; Dewolf WE; Quinn C; West J; Polizzi BJ; So CY; Holmes DJ; Reed SL; Heath RJ; Payne DJ; Rock CO; Wallis NG
    Biochem J; 2003 Mar; 370(Pt 3):1055-62. PubMed ID: 12487627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antimicrobial action of triclosan-lysozyme complex against skin pathogens mediated through drug-targeted delivery mechanism.
    Hoq MI; Ibrahim HR
    Eur J Pharm Sci; 2011 Jan; 42(1-2):130-7. PubMed ID: 21078387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan.
    Ward WH; Holdgate GA; Rowsell S; McLean EG; Pauptit RA; Clayton E; Nichols WW; Colls JG; Minshull CA; Jude DA; Mistry A; Timms D; Camble R; Hales NJ; Britton CJ; Taylor IW
    Biochemistry; 1999 Sep; 38(38):12514-25. PubMed ID: 10493822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
    Gerusz V; Denis A; Faivre F; Bonvin Y; Oxoby M; Briet S; LeFralliec G; Oliveira C; Desroy N; Raymond C; Peltier L; Moreau F; Escaich S; Vongsouthi V; Floquet S; Drocourt E; Walton A; Prouvensier L; Saccomani M; Durant L; Genevard JM; Sam-Sambo V; Soulama-Mouze C
    J Med Chem; 2012 Nov; 55(22):9914-28. PubMed ID: 23092194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whither triclosan?
    Russell AD
    J Antimicrob Chemother; 2004 May; 53(5):693-5. PubMed ID: 15073159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
    Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
    Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.